首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

2039038

急性外陰陰道念珠菌症治療市場：依藥物類型、給藥途徑、通路及地區分類

Acute Vulvovaginal Candidiasis Treatment Market,By Drug Type, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年04月30日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，急性外陰陰道念珠菌症治療市場規模將達到 10.5 億美元，到 2033 年將達到 14.7 億美元。預計 2026 年至 2033 年的複合年成長率將達到 5.2%。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	10.5億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	5.20%	預計金額（2033 年）	14.7億美元

急性外陰陰道念珠菌症是一種真菌感染疾病，會影響陰道和外陰開口處的組織。它是由念珠菌屬真菌引起。此感染疾病的症狀包括劇烈搔癢、發炎和白色濃稠分泌物。輕度感染疾病可透過單次服用抗真菌藥物或塗抹抗真菌乳膏治愈，但重度感染疾病需要長期治療。

市場動態

市場參與企業正專注於非內部成長活動，例如收購，預計這些活動將擴大產品系列併鞏固其在全球市場的地位，從而在預測期內推動全球市場成長。例如，2020年6月7日，ANI Pharmaceuticals Inc.以300萬美元的價格從私人公司收購了Fluconazole片（50毫克、100毫克、150毫克和200毫克）。此次收購使ANI Pharmaceuticals的產品系列新增了一種用於治療急性外陰陰道念珠菌症的產品。

預計在預測期內，針對外陰陰道念珠菌症治療方法研發的投入增加將推動全球急性外陰陰道念珠菌症治療市場的成長。例如，根據2018年發表在《BMC微生物學雜誌》上的一篇論文，當口服藥物製黴菌素（一種外陰陰道念珠菌症病治療藥物）用於感染白色念珠菌的陰道上皮細胞（VECs）時，與未感染細胞相比，細胞內IFN-γ、IL-17和IgG的水平升高。因此，制黴菌素能夠活化宿主對抗白色念珠菌的防禦機制。

本報告的主要特點

本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
本節根據以下參數介紹全球急性外陰陰道念珠菌症治療市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球急性外陰陰道念珠菌症治療市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球急性外陰陰道念珠菌症治療市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第8章競爭情勢

Mycovia Pharmaceuticals, Inc
Scynexis, Inc
Basilea Pharmaceutica Ltd
Astellas Pharma Inc
Grupo Ferrer Internacional, SA
Pacgen Life Science Corporation
NovaDigm Therapeutics, Inc.
Cidara Therapeutics, Inc.
Amplyx Pharmaceuticals Inc.
Pfizer, Inc

第9章分析師建議

機會
分析師意見
Coherent Opportunity Map (COM)

第10章：參考文獻與分析方法

參考
分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI4315

Acute Vulvovaginal Candidiasis Treatment Market is estimated to be valued at USD 1,050 Mn in 2026 and is expected to reach USD 1,470 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,050 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.20%	2033 Value Projection:	USD 1,470 Mn

Acute vulvovaginal candidiasis is a yeast infection, which affects the vagina and tissues present at the opening of the vulva. It is caused by fungus Candida species. The symptoms for the infection are intense itchiness, inflammation, thick, white discharge, and others. Mild infection can be cured with a single dose of the antifungal agent or by application of antifungal creams while severe infections require longer treatment.

Market Dynamics

Market players are indulged in inorganic activities such as acquisition, which is expected to expand their product portfolio and strengthen their position in the global market, and drive growth of the global market over the forecast period. For instance, on June 7, 2020, ANI Pharmaceuticals Inc. acquired Fluconazole Tablets (50mg, 100mg, 150mg, and 200mg) from a private company for US$ 3 million. Thus, ANI Pharmaceuticals expanded their product portfolio by including drugs for the treatment of acute vulvovaginal candidiasis.

Increasing research and development for developing treatment for vulvovaginal candidiasis is expected to drive growth of the global acute vulvovaginal candidiasis treatment market over the forecast period. For instance, according to the article published in the BMC Microbiology Journal: 2018, Nystatin, an oral medication for the treatment of vulvovaginal candidiasis, when used in the vaginal epithelial cells (VEC) infected with Candidiasis albicans, increased the levels of IFN-Y, IL-17, and IgG in the cells as compared to the uninfected cells. Therefore, Nystatin upregulates the host defense mechanism against Candida albicans.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global acute vulvovaginal candidiasis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global acute vulvovaginal candidiasis treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the acute vulvovaginal candidiasis treatment market

Acute Vulvovaginal Candidiasis Treatment Market Segmentation

By Drug Type (Revenue, USD Mn, 2021-2033)
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
By Route of Administration (Revenue, USD Mn, 2021-2033)
- Oral
- Intravenous
- Topical
By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Acute Vulvovaginal Candidiasis Treatment Market, By Region (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Mycovia Pharmaceuticals, Inc.
- Scynexis, Inc.
- Basilea Pharmaceutica Ltd.
- Astellas Pharma Inc.
- Grupo Ferrer Internacional, S.A.
- Pacgen Life Science Corporation
- NovaDigm Therapeutics, Inc.
- Cidara Therapeutics, Inc.
- Amplyx Pharmaceuticals Inc.
- Pfizer, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trend

4. Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Clotrimazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Nystatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Fluconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Ketoconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Terbinafine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Terconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Acute Vulvovaginal Candidiasis Treatment Market, By Region, 2021 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Mycovia Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Scynexis, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Basilea Pharmaceutica Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Grupo Ferrer Internacional, S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pacgen Life Science Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
NovaDigm Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cidara Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amplyx Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer, Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies